ストックスクリーナーアプリを入手
3.53
1.73%
0.06
前日終値:
$3.47
開ける：
$3.5
24時間の取引高:
3.14M
Relative Volume:
0.79
時価総額：
$637.20M
収益：
-
当期純損益:
$-217.44M
株価収益率:
-1.6267
EPS:
-2.17
ネットキャッシュフロー:
$-205.20M
1週間 パフォーマンス:
+0.86%
1か月 パフォーマンス:
+6.97%
6か月 パフォーマンス:
+14.98%
1年 パフォーマンス:
+18.06%
1日の値動き範囲:
$3.3314
$3.535
1週間の範囲:
$3.29
$3.535
52週間の値動き範囲:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
PRME を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.53 | 626.37M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-05-20 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-12-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-05-20 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2024-04-22 | 開始されました | Chardan Capital Markets | Buy |
| 2024-04-08 | 開始されました | TD Cowen | Buy |
| 2024-04-03 | 開始されました | Wedbush | Outperform |
| 2024-01-16 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-08 | 開始されました | Citigroup | Neutral |
| 2023-10-09 | 開始されました | BMO Capital Markets | Outperform |
| 2023-07-31 | 開始されました | Guggenheim | Buy |
| 2023-04-18 | 開始されました | Stifel | Buy |
| 2022-11-14 | 開始されました | Goldman | Neutral |
| 2022-11-14 | 開始されました | JP Morgan | Overweight |
| 2022-11-14 | 開始されました | Jefferies | Buy |
| 2022-11-14 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Prime Medicine Inc (PRME) 最新ニュース
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize - Benzinga
Prime: Maintaining "Buy" On Solidified Catalysts For Wilson's Disease And Beyond - Seeking Alpha
Prime Medicine (NYSE:PRME) Trading Down 3.3%Here's What Happened - MarketBeat
LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases - Insider Monkey
Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data - Insider Monkey
10 Best Biotech Penny Stocks to Buy According to Analysts - Insider Monkey
Lifesci Capital Predicts Prime Medicine FY2025 Earnings - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Down 3.8%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Down 4.2%Should You Sell? - MarketBeat
Prime Medicine (NASDAQ:PRME) Upgraded at Lifesci Capital - MarketBeat
LifeSci Capital Initiates Coverage of Prime Medicine (PRME) with Outperform Recommendation - Nasdaq
How Prime Medicine Inc. stock reacts to oil pricesEvening Star Patterns & Free Dynamic Investment Techniques - bollywoodhelpline.com
Lifesci Capital Begins Coverage on Prime Medicine (NYSE:PRME) - MarketBeat
LifeSci Capital Initiates Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $6 - 富途牛牛
Prime Medicine: Buy Rating on Prime Editing Platform Targeting High-Value Liver and Lung Genetic Diseases, Led by PM577 in Wilson’s Disease - TipRanks
Prime Medicine initiated with an Outperform at LifeSci Capital - TipRanks
LifeSci Initiates Prime Medicine at Outperform With $6 Price Target - marketscreener.com
Prime Medicine, Inc.(NasdaqGM: PRME) added to S&P Biotechnology Select Industry Index - marketscreener.com
Prime Medicine announces NEJM publication of PM359 data - MSN
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Recap: How Prime Medicine Inc. stock reacts to oil pricesWatch List & Safe Entry Trade Reports - Улправда
Risks Report: Why Prime Medicine Inc. stock remains resilient2025 Market Trends & Real-Time Buy Signal Notifications - Улправда
What technical charts say about Prime Medicine Inc. stockEarnings Overview Report & AI Powered Market Entry Strategies - Улправда
Why Prime Medicine Inc. stock remains resilientTrade Exit Summary & Weekly High Return Stock Forecasts - Улправда
Can Prime Medicine Inc. stock hit record highs againJuly 2025 News Drivers & Weekly High Conviction Ideas - Улправда
Can Prime Medicine Inc. stock withstand economic slowdownTrade Signal Summary & Weekly Top Gainers Alerts - Улправда
Is Prime Medicine Inc. stock in correction or buying zone2025 Stock Rankings & Consistent Growth Equity Picks - DonanımHaber
Profit Recap: How Prime Medicine Inc. stock reacts to oil pricesRate Hike & Accurate Intraday Trading Signals - Улправда
Prime Medicine Earnings Notes - Trefis
Prime Medicine's Market Cap Up US$161m Following Year Of Insider Stock Buying - simplywall.st
Prime Medicine’s Stock Fluctuations: How Genomic Advances Steer Performance - StocksToTrade
Prime Medicine (NYSE:PRME) Shares Gap UpShould You Buy? - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Gap UpStill a Buy? - MarketBeat
Prime Medicine Announces The New England Journal of - GlobeNewswire
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease - Sahm
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Prime Medicine (NYSE:PRME) Stock Price Up 10.2%Still a Buy? - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Up 11.1%Here's What Happened - MarketBeat
Will Prime Medicine Inc. stock deliver better than expected guidance2025 Sector Review & Safe Capital Preservation Plans - Newser
Prime Medicine (PRME) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Prime Medicine (NASDAQ:PRME) Stock Price Down 7.3%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Down 7.2%Here's Why - MarketBeat
PRME: Prime editing advances with focused clinical programs and data expected in 2027 - TradingView — Track All Markets
Prime Medicine (PRME) Competitors and Alternatives 2025 - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference - The Manila Times
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates - MSN
Prime Medicine transferred with Neutral rating at JPMorgan - MSN
How interest rate cuts could boost Prime Medicine Inc. stockQuarterly Trade Summary & Intraday High Probability Alerts - newser.com
How strong is Prime Medicine Inc. stock balance sheetRate Hike & Growth Oriented Trading Recommendations - newser.com
Prime Medicine Target of Unusually High Options Trading (NYSE:PRME) - MarketBeat
Prime Medicine Inc (PRME) 財務データ
収益
当期純利益
現金流量
EPS
Prime Medicine Inc (PRME) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| NELSEN ROBERT | Director |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners X, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| Liu David R. | 10% Owner |
Jun 30 '25 |
Buy |
2.52 |
21,000 |
52,830 |
20,240,945 |
| Liu David R. | 10% Owner |
Jun 23 '25 |
Buy |
2.16 |
21,000 |
45,402 |
20,219,945 |
| Liu David R. | 10% Owner |
Jun 16 '25 |
Buy |
1.49 |
21,000 |
31,196 |
20,198,945 |
| Liu David R. | 10% Owner |
Jun 11 '25 |
Buy |
1.60 |
21,000 |
33,590 |
20,177,945 |
| Brudnick Richard | Chief Business Officer |
May 20 '25 |
Buy |
1.19 |
20,000 |
23,790 |
20,000 |
| LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
| Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
0.57%
大文字化:
|
ボリューム (24 時間):